AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33539915 — intervention group
Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173
Study 33320868 — intervention group
Group type: EXPERIMENTAL
Intervention: NO3‐ rich beetroot juice (12.4 mmol NO3‐)
Number of subjects: 11
Study 33320868 — intervention group
Group type: COMPARATOR
Intervention: Positive-control (140 ml of water)
Number of subjects: 11
Study 33320868 — intervention group
Group type: COMPARATOR
Intervention: Placebo-trial (140 ml NO3‐ depleted beetroot juice)
Number of subjects: 11
Study 33320868 — intervention group
Group type: COMPARATOR
Intervention: Negative-control (140 ml of water)
Number of subjects: 11
Study 35388235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine 1.0 mg/kg body weight (BW), q12h for 14 days
Number of subjects: 19
Study 35388235 — intervention group
Group type: COMPARATOR
Intervention: Nebulized budesonide 1 μg/kg, q12h for 14 days
Number of subjects: 19
Study 35028769 — intervention group
Group type: EXPERIMENTAL
Intervention: VS+PBMT (vaginal stretching combined with photobiomodulation therapy)
Number of subjects: 103
Study 35028769 — intervention group
Group type: COMPARATOR
Intervention: VS+shamPBMT (vaginal stretching combined with sham photobiomodulation therapy)
Number of subjects: 103
Study 33575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based systemic rehabilitation (50-minute sessions, three times weekly for 12 weeks)
Number of subjects: 35
Study 33575340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based systemic rehabilitation
Number of subjects: 35
Study 33575340 — intervention group
Group type: COMPARATOR
Intervention: Education-based rehabilitation at home
Number of subjects: 35
Study 33405346 — intervention group
Group type: EXPERIMENTAL
Intervention: Mislabeled objects during encoding context
Number of subjects: 20
Study 33405346 — intervention group
Group type: COMPARATOR
Intervention: Correctly labeled objects during encoding context
Number of subjects: 20
Study 32292360 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug plus psychotherapy (DPP) - olanzapine and metacognitive training
Number of subjects: 41
Study 32292360 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (DT) - olanzapine only
Number of subjects: 41
Study 32292360 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP group
Number of subjects: 41
Study 32292360 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 41
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with neoadjuvant radiotherapy (29%)
Number of subjects: 226
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with adjuvant radiotherapy (37%)
Number of subjects: 226
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy with surgery (22%)
Number of subjects: 226
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitive chemoradiotherapy (7%)
Number of subjects: 226
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (5%)
Number of subjects: 226
Study 34510258 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment (80% completed treatment with curative intent)
Number of subjects: 226
Study 35221683 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Disease Management (IDM) intervention
Number of subjects: 571
Study 32855884 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroretinography (ERG)
Number of subjects: 97
Study 32855884 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Automated Perimetry
Number of subjects: 97
Study 32855884 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Discrimination
Number of subjects: 97
Study 32855884 — intervention group
Group type: EXPERIMENTAL
Intervention: ERG Amplitudes and Isopter Area
Number of subjects: 97
Study 34897226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Naltrexone (NTX)
Number of subjects: 156
Study 34897226 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 32330571 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin (1.6 mg/d) for 16 weeks, n=24
Number of subjects: 115
Study 32330571 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n=23
Number of subjects: 115
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully vaccinated individuals (n = 1114)
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinopharm vaccine
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Cansino vaccine
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinovac vaccine
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated individuals (n = 1114)
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakthrough cases in men
Number of subjects: 2467
Study 36249252 — intervention group
Group type: EXPERIMENTAL
Intervention: Age group 18-33 years
Number of subjects: 2467
Study 32019609 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week RUFIT-NZ program
Number of subjects: 308
Study 32019609 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 308
Study 32167792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2100 mg/day)
Number of subjects: 56
Study 32167792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 32167792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 56
Study 33392664 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMOCIN® patch
Number of subjects: 64
Study 33392664 — intervention group
Group type: COMPARATOR
Intervention: No systematic treatment (control)
Number of subjects: 64
Study 32889172 — intervention group
Group type: EXPERIMENTAL
Intervention: Local p16 testing by immunohistochemistry (IHC)
Number of subjects: 176
Study 32889172 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV RNA in situ hybridisation (HPV RNA ISH)
Number of subjects: 176
Study 36684501 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 300 mg/day
Number of subjects: 56
Study 36684501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 33921935 — intervention group
Group type: EXPERIMENTAL
Intervention: ViroTrack Dengue Serostate
Number of subjects: 484
Study 32376341 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state EEG recordings and dynamic analysis of design fluency test
Number of subjects: 34
Study 32376341 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-band hyper-connections
Number of subjects: 34
Study 32376341 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hyperconnectivity within the posterior hub of the Default Mode Network
Number of subjects: 34
Study 36123783 — intervention group
Group type: EXPERIMENTAL
Intervention: EMP16-120/40 (120 mg orlistat/40 mg acarbose)
Number of subjects: 156
Study 36123783 — intervention group
Group type: EXPERIMENTAL
Intervention: EMP16-150/50 (150 mg orlistat/50 mg acarbose)
Number of subjects: 156
Study 36123783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 33359193 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient PCI
Number of subjects: 1905
Study 33359193 — intervention group
Group type: COMPARATOR
Intervention: Inpatient PCI
Number of subjects: 1905
Study 33639331 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for OCD
Number of subjects: 110
Study 33639331 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) for MDD
Number of subjects: 110
Study 33639331 — intervention group
Group type: COMPARATOR
Intervention: Deep brain stimulation (DBS) for OCD and MDD
Number of subjects: 110
Study 32934372 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma therapy
Number of subjects: 39
Study 32934372 — intervention group
Group type: COMPARATOR
Intervention: Propensity score–matched controls
Number of subjects: 39
Study 35775199 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing insecurity (i.e., foreclosure/eviction threat, history of homelessness, late rent)
Number of subjects: 361
Study 35775199 — intervention group
Group type: EXPERIMENTAL
Intervention: Household crowding
Number of subjects: 361
Study 35775199 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding exclusivity intention during the early postnatal period
Number of subjects: 361
Study 33821768 — intervention group
Group type: EXPERIMENTAL
Intervention: IBU monotherapy
Number of subjects: 1477
Study 33821768 — intervention group
Group type: EXPERIMENTAL
Intervention: APAP monotherapy
Number of subjects: 1477
Study 34748059 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral (IT) tracer injection (2 depots of 1 mL indocyanine green-[99mTc]Tc-nanocolloid)
Number of subjects: 113
Study 34748059 — intervention group
Group type: COMPARATOR
Intervention: Intraprostatic (IP) tracer injection (4 depots of 0.5 mL indocyanine green-[99mTc]Tc-nanocolloid)
Number of subjects: 113
Study 32558047 — intervention group
Group type: EXPERIMENTAL
Intervention: mini-CEX rating form
Number of subjects: 36
Study 34488392 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid resuscitation guided by POEM score >3
Number of subjects: 31
Study 34488392 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring without POEM score
Number of subjects: 31
Study 32367880 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT) for 5 days a week for 3 weeks
Number of subjects: 40
Study 32367880 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal Shock Wave therapy (ESWT) once a week for 3 weeks
Number of subjects: 40
Study 35279948 — intervention group
Group type: COMPARATOR
Intervention: HAR (Restylane, the gold standard HA filler)
Number of subjects: 173
Study 34516492 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 > 0.85
Number of subjects: 42
Study 34516492 — intervention group
Group type: COMPARATOR
Intervention: FIO2 < 0.7
Number of subjects: 42
Study 32150855 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB group (half‐body UVB irradiation, twice weekly over 6 months, with 1 standard erythema dose (SED))
Number of subjects: 78
Study 32150855 — intervention group
Group type: COMPARATOR
Intervention: VD group (5600 International units (IU) cholecalciferol supplementation once a week)
Number of subjects: 78
Study 32150855 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (UVB and VD)
Number of subjects: 78
Study 35973626 — intervention group
Group type: EXPERIMENTAL
Intervention: Local prophylactic antibiotic therapy with vancomycin loaded calcium sulfate beads
Number of subjects: 83
Study 33888426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion
Number of subjects: 51
Study 34628439 — intervention group
Group type: EXPERIMENTAL
Intervention: Systems Analysis and Improvement Approach (SAIA)
Number of subjects: 2406
Study 34628439 — intervention group
Group type: COMPARATOR
Intervention: Usual procedures (Control)
Number of subjects: 2406
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with FOLFIRINOX (oxaliplatin 85 mg/m2, irinotecan 180 mg/m2, leucovorin 400 mg/m2, fluorouracil 2400 mg/m2 intravenously every 14 days for 6 cycles), followed by chemoradiotherapy (50 Gy during 5 weeks and 800 mg/m2 concurrent oral capecitabine twice daily for 5 days per week), total mesorectal excision, and adjuvant chemotherapy (3 months of modified FOLFOX6 or capecitabine).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (chemoradiotherapy, total mesorectal excision, and adjuvant chemotherapy for 6 months).
Number of subjects: 461
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (during neoadjuvant chemotherapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (during chemoradiotherapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (during adjuvant chemotherapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (during adjuvant chemotherapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (serious adverse events during the whole treatment period).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (serious adverse events during the whole treatment period).
Number of subjects: 461
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (serious adverse events during adjuvant therapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (serious adverse events during adjuvant therapy).
Number of subjects: 461
Study 33862000 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy group (treatment-related deaths).
Number of subjects: 461
Study 33862000 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (treatment-related deaths).
Number of subjects: 461
Study 34273650 — intervention group
Group type: EXPERIMENTAL
Intervention: Black chokeberry dried pomace (30 g/kg of feed)
Number of subjects: 480
Study 34273650 — intervention group
Group type: EXPERIMENTAL
Intervention: Black currant dried pomace (30 g/kg of feed)
Number of subjects: 480
Study 34273650 — intervention group
Group type: EXPERIMENTAL
Intervention: Raspberry dried pomace (30 g/kg of feed)
Number of subjects: 480
Study 34273650 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 480
Study 32629992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat β‐glucan (12g/day)
Number of subjects: 49
Study 32629992 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat arabinoxylan (12g/day)
Number of subjects: 49
Study 32629992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 49
Study 35359769 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese version of the Brief State Rumination Inventory (BSRI)
Number of subjects: 512
Study 35359769 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination induction group (n=27)
Number of subjects: 512
Study 35359769 — intervention group
Group type: COMPARATOR
Intervention: Distraction group (n=27)
Number of subjects: 512
Study 35368495 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school physical activity intervention for 9 months
Number of subjects: 280
Study 35368495 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 280
Study 33427961 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 IU vitamin D3/day
Number of subjects: 378
Study 33427961 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU vitamin D3/day
Number of subjects: 378
Study 33427961 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D3/day
Number of subjects: 378
Study 34533848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for sociability, sexuality, and risk/aggression
Number of subjects: 433
Study 34533848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for self-perception
Number of subjects: 433
Study 34533848 — intervention group
Group type: EXPERIMENTAL
Intervention: Valuation of risk/aggression
Number of subjects: 433
Study 34533848 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol expectancies for sexuality and self-perception
Number of subjects: 433
Study 34533848 — intervention group
Group type: EXPERIMENTAL
Intervention: Valuation of self-perception
Number of subjects: 433
Study 32052116 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide receptor radionuclide therapy (PRRT)
Number of subjects: 0
Study 32052116 — intervention group
Group type: COMPARATOR
Intervention: Hybrid SSTR-SPECT/CT or -PET/CT
Number of subjects: 0
Study 33065729 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive exposure to blue‐enriched polychromatic lighting for three 20‐minute intervals including 10 minutes of exercise
Number of subjects: 20
Study 33065729 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 32078815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV alone at weeks 0 and 12 and Ad26.Mos.HIV plus adjuvanted gp140 at weeks 24 and 48 (Group 1)
Number of subjects: 36
Study 32078815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV plus adjuvanted gp140 at weeks 0, 12, and 24 (Group 2)
Number of subjects: 36
Study 32078815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.Mos.HIV alone at week 0 and Ad26.Mos.HIV plus adjuvanted gp140 at weeks 8 and 24 (Group 3)
Number of subjects: 36
Study 32078815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.5 mL of 0.9% saline)
Number of subjects: 36
Study 32078815 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccine regimens
Number of subjects: 36
Study 32078815 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened group 3 regimen in rhesus monkeys
Number of subjects: 36
Study 35661378 — intervention group
Group type: EXPERIMENTAL
Intervention: TTP399 (800 mg)
Number of subjects: 23
Study 35661378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 32580838 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 30-minute intervals with a pulse dose of 5 mL (Group A)
Number of subjects: 170
Study 32580838 — intervention group
Group type: COMPARATOR
Intervention: Programmed intermittent epidural bolus (PIEB) plus patient-controlled epidural analgesia (PCEA) at 60-minute intervals with a pulse dose of 10 mL (Group B)
Number of subjects: 170
Study 34726317 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-energy diet (CLED) - 8 weeks/56 days of daily Optifast 820 kcal (3430 kJ) diet
Number of subjects: 79
Study 34726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED) - 2 days of Optifast and 5 days of a Mediterranean diet/week for 28 weeks
Number of subjects: 79
Study 34726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ILED and CLED)
Number of subjects: 79
Study 34726317 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent low-energy diet (ILED)
Number of subjects: 79
Study 34726317 — intervention group
Group type: COMPARATOR
Intervention: Continuous low-energy diet (CLED)
Number of subjects: 79
Study 32803265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry/damp followed by wet cleaning
Number of subjects: 48
Study 32803265 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet cleaning followed by dry/damp cleaning
Number of subjects: 48
Study 32803265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry/damp and wet cleaning applied the same day
Number of subjects: 48
Study 32803265 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry/damp and wet cleaning (combined)
Number of subjects: 48
Study 36162373 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium alginate dressings with ZnO nanoparticles (G1; n = 16)
Number of subjects: 26
Study 36162373 — intervention group
Group type: COMPARATOR
Intervention: Calcium alginate dressings without ZnO nanoparticles (G2; n = 10)
Number of subjects: 26
Study 34720688 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex social accountability intervention
Number of subjects: 0
Study 34720688 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 34170842 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular closure devices (VCDs)
Number of subjects: 694
Study 34170842 — intervention group
Group type: COMPARATOR
Intervention: No vascular closure devices (no VCD)
Number of subjects: 694
Study 34574492 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Programs (PA)
Number of subjects: 307
Study 34574492 — intervention group
Group type: COMPARATOR
Intervention: Men compared to women
Number of subjects: 307
Study 34574492 — intervention group
Group type: COMPARATOR
Intervention: People with at least primary education compared to those with no education
Number of subjects: 307
Study 34706835 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention group (gubernaculum preserving laparoscopic orchiopexy)
Number of subjects: 120
Study 34706835 — intervention group
Group type: COMPARATOR
Intervention: Cutting group (gubernaculum cutting laparoscopic orchiopexy)
Number of subjects: 120
Study 32374371 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total mesorectal excision by upper quartile-scoring surgeons
Number of subjects: 176
Study 32374371 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic total mesorectal excision by lower quartile-scoring surgeons
Number of subjects: 176
Study 34460933 — intervention group
Group type: EXPERIMENTAL
Intervention: GOP infusion (n = 14)
Number of subjects: 25
Study 34460933 — intervention group
Group type: COMPARATOR
Intervention: Very Low-Calorie Diet (VLCD) (n = 22)
Number of subjects: 25
Study 34460933 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB) (n = 21)
Number of subjects: 25
Study 34460933 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline control (n = 11)
Number of subjects: 25
Study 34217955 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided graded exercise self-help (GES)
Number of subjects: 0
Study 36008202 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intra-arterial monitoring
Number of subjects: 242
Study 36008202 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oscillometric monitoring
Number of subjects: 242
Study 34862226 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for clinical trial participation
Number of subjects: 213
Study 32078917 — intervention group
Group type: EXPERIMENTAL
Intervention: Working Memory Training (WMT), 5-week adaptive program
Number of subjects: 76
Study 32078917 — intervention group
Group type: COMPARATOR
Intervention: Passive waiting-list control group (CG)
Number of subjects: 76
Study 34583841 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term psychodynamic psychotherapy (LPP)
Number of subjects: 326
Study 34583841 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-focused therapy (SFT)
Number of subjects: 326
Study 34583841 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic psychotherapy (SPP)
Number of subjects: 326
Study 32294346 — intervention group
Group type: EXPERIMENTAL
Intervention: SEP‐363856 (50 mg or 75 mg)
Number of subjects: 245